Ola Dale
| Epost | ola.dale@ntnu.no |
| Fasttelefon | 72826401 |
| Kontoradresse | AHL*341.03.008, Prinsesse Kristinas gate 3 |
| Stilling | Professor |
| Enhet | Institutt for sirkulasjon og bildediagnostikk |
CV resyme og publikasjoner siste 5 år
Main Research AreasClincial pharmacology/pharmacogenetics of opioids and pain
Clinical research in anesthesiology
Experimental pharmacology of anesthetics and other drugs
Pain epidemiology
Education
1989: Certified Specialist, Clinical Pharmacology
1988: Certified Specialist, Anesthesiology
1986: Dr. med. Norwegian University of Science and Technology, Norway
1976: M.D. (Norwegian Medical License)
1974: Graduation in Medicine (cand. med), University of Bergen, Norway
Appointments:
2006 Visiting professor. Goethe Universität, Frankfurt, Germany (4 months)
1999 Visiting professor, Dept of Anesthesiology,
1997 Professor of Pharmacology/Anesthesiology, Norwegian
1996-97 Medical Coordinator RIT2000 (Hospital Development/Project organisation)/Head of Planning and Development Section,
1994 Professor of Pharmacology/Anesthesiology, Norwegian
1990-94 Consultant, Clinical Pharmacology, Department of Pharmacology and Toxicology, Norwegian
1988 Post Doctoral Fellow, (NFR), Department of Pharmacology and Toxicology,
1987 -88 Senior Resident, Department of Anesthesiology,
1986-87 Senior Resident, Clinical Pharmacology, Department of Pharmacology and Toxicology, Norwegian University of Science and Technology
1985-86 Fogarty Fellow (NIH), Department of Anesthesiology, University of Arizona
1985 Senior Resident, Department of Anesthesiology,
1984-85 Resident, Clinical Pharmacology, Department of Pharmacology and Toxicology, Norwegian University of Science and Technology,
1980-83 Research Fellow (NFR) at Department of Pharmacology and Toxicology, Norwegian University of Science and Technology, Trondheim
1979 Resident, Internal Medicine (12 months), St.Olavs University Hospital, Trondheim
1977- 79 Resident, Anesthesiology, , St.Olavs University Hospital, Trondheim
1976: Military service, Trondheim
1974-75: Internship, County Hospital of Voss and county of Melhus
Ongoing Research supervision
Supervising four doctoral students (two as major responsible, assisting two). Master students
Major service
2008 Member governmental l advisory for new regluations of medical research
2008- Member advisory Board (Propose actions to fascilitate pharmaceutical research in
2007 Member, Norwegian Board of Technology
2007 Member, Executive Committee, Council for International Organizations for Medical Sciences (CIOMS) in
2006 Member, Board, The Royal Norwegian Society of Science and Letters
2006 Member, Editorial board, The Journal of the Norwegian Medical Association
2004-- Member, Advisory Board of the
2004-05 Member, Licensing Board, Anesthesiology
2003 Member, National Committee of Medical Research Ethics
2003 Member, Ethics Advisory Board for Norwegian Patent Bureau
2002-06 Theme group leader (Geriatry, Pain and Pharmacology) in HUNT.
1998-02 Head of Dept. of Anesthesia and Medical Imaging, NTNU
1994 –01 Member of the board of the Medical School, NTNU
1994-02: Chairman, Regional Committee of Medical Research Ethics (IRB),
1993- Associate editor, Acta Anesthesiol Scand,
1992-94: Chairman, Norwegian Society of Clinical Pharmacologists, treasurer 94-96
1992-96: Chairman, Drugs and Therapeutics Committee,
1991-92: Member, Research Committee, Medical School, NTNU,
1988-89: Junior Member, Licensing Board, Clinical Pharmacology,
1984-94: Associate editor, Survey of Anesthesiology
1984-86: Deputy member/member, Board of the Medical School, NTNU,
Research abroad and international collaboration
2006 : 4.5 months research sabbatical: Institut für Klinische Pharmakologie, Johann von Goethe –Universität, Frankfurt am Main, Germany (sponsor J. Lötsch)
1999-00. (8 months) Research sabbatical: Department of Anesthesiology, University of Washington, Seattle, Washington. Sponsor Evan D. Kharasch. Short stay also in 2001and 2002. Five papers published.2002: A Medical student from Trondheim did collaborative thesis at the University of Washington
1985-86: (12 months) Fogarty Post Doctoral Fellowship (NFR/NIH), Department of Anesthesiology,
Cooperative research with Professor Thorsteinn Loftsson, Department of Pharmacy, University of Iceland
Industrial collaboration in Clinical Trials
Clinical Trials: (Phase IV) Pharmacia; (Desflurane recovery characteristic). (Phase 2)–Pharmacia, Sweden (Pharmacokinetics of the anesthetic eltanolone: gender aspects). (Phase 1)of new sprayer device – Optinose A/S, Norway (nasal sprayer technology/device)
GCP Course: Clinical Trials, Trondheim 1999
Clinical studies in patients (independent of pharmaceutical industry) as well as volunteer studies on drug disposition All are published or under publication (except the Desflurane study). Also taken part in preparation groups/advisory boards for clinical trials, and chaired session/taken part in kick off meetings. Role usually project leader.
Teaching experience
Performed teaching from 1981 to nurse students, nurses, post-graduate nurse students, toxicology students, medical students, post-graduate for medical doctors .Fields: Anesthesiology, Pharmacology, Clinical Pharmacology, Medical Ethics/Research Ethics
Run mandatory national 3 day course on Pharmacology for anesthesia residents over 11 years. Given a number of invited lectures on international conferences
Dissemination
Feature articles, letters to the editor, interviews in popular magazines, local and national papers/journals in the fields of medical research ethics, clinical pharmacology, research ethics, pharmacotherapeutic organisational matters, and matters concerning hospitals and their organisation.
Publications 2003 – dd
I Original publications
Dale O, Nilsen T, Bjørgaas T,.Borkamo A, Aadahl P The time course of exhaled ethane in six intensive care cases. Acta Anaesth Scand 2008; 52:869-71
Dale O, Piribauer M, Kaasa S, Moksnes M, Knobel H, Klepstad P. A double-blind randomized clinical and a pharmacokinetic comparison between double-dose of immediate morphine versus single-dose morphine at bedtime to cancer patients. J Pain Symptom Management 2008 May 24. [Epub ahead of print]
Moksnes K, Fredheim OM,, Klepstad K, Kaasa S,Angelsen A, Nilsen T, Dale O. Early pharmacokinetics of nasal fentanyl: Is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008; 64:497-502. Epub 2008 Jan 6.
Stenseth R, Nilsen T, Haaverstad R, Vitale N, Dale O. Frequent sampling of allows detection of short and rapid surges of exhaled ethane during cardiac surgery. Perfusion 2007;22:0391-6
Dale O, Thoner J, Nilsen T, Tveita T, Borchgrevink PC, Klepstad P. Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. Eur J Clin Pharmacol, 2007; 63:837-42
Fredheim OMS, Borchgrevink PC, Klepstad, Kaasa S, Dale O. Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects.Eur J Pain. 2006 Nov 16; [Epub ahead of print]
Dale O, Nilsen T, Olaussen G, Tvedt KE, Skorpen F, Smidsrød O, Vårum K. Transepithelial transport of morphine and mannitol in Caco-2 cells: The influence of chitosans of different molecular weights and degrees of acetylation. J Pharm Pharmacol 2006: 58(7):909-15.
Fredheim OMS, Borchgrevink PC, Hegrenæs L, Kaasa S, Dale O, Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9 months follow-up study. J Pain Symptom Management 2006; 32 (2):180-5.
Pleym H, Wahba A, Videm V, Åsberg A, Lydersen S,Bjella L, Dale O, Stenseth R. Increased fibrinolysis and platelet activation in elderly patients undergoing coronary bypass surgery. Anesth Analg 2006;102:660-7
Pleym H, Videm V, Wahba A,Åsberg A, Amundsen T, Bjella B, Dale O, Stenseth R. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. Eur J Cardio-Thoracic Surg 2006;29:933-40
Fredheim OMS, Kaasa S, Dale O, Klepstad P, Landrø NI, Borchgrevink PC. O Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine months follow-up study. Palliative Medicine 2006; 20: 35-41
Rakvåg TT, Klepstad P, Baar C, Kavm T-M, Dale O, Kaasa S, Krokan HE, Skorpen F. The Val158Met polymorphism of the human cathecol-O-mehyl transferase (COMT) gene may influence morphine requirements in cancer pain patient. Pain. 2005;116::73-8
Pleym H, Tjomsland O, Åsberg A, Lydersen S, Wahba A, Bjella L, Dale O, Stenseth R. Effects of autotransfusion of mediastinal shed blood on biochemical markers of myocardial damage in coronary surgery. Acta Anaesthesiol Scand. 2005;49:1248-54.
Klees TM, Sheffels P, Dale O, Kharasch ED. Metabolism of alfentanil by cytochrome P4503A (CYP3A) isoforms. Drug Metab Disp 2005;33:303-11
Klepstad P, Hilton P, Moen J, Kaasa S, Borchgrevink PC, Zahlsen K, Dale O. Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study. BMC Clin Pharmacol 2004; 4:7
Klepstad P, Rakvåg T, Kaasa S, Holthe M, Dale O, Borchgrevinck PC, Baar C, Vikan T, Krokan HE, Skorpen S. The A118 A>G polymorphism of the human µ-opioid receptor gene increases morphine requirements in patients with pain caused by malignant disease. Acta Anaesth Scand 2004; 48: 1232-9
Pleym H, Stenseth R, Wiseth R, Karevold A, Dale O. Supplemental remifentanil during coronary artery bypass grafting does not reduce the incidence of perioperative ischemic episodes but is followed by a transient postoperative cardiac depression. Acta Anaesth Scand 2004; 48:1155-62.
Dale O, Sheffels P, Kharasch ED. Disposition of intravenous, oral and rectal methadone in healthy volunteers. Br J Clin Pharmacol 2004; 58:156-62
Pleym H, Stenseth R, Wahba A, Bjella L, Tromsdal A, Karevold A, Dale O. Prophylactic treatment with desmopressin does not reduce postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg; 2004;98:578-84
Klepstad P, Dale O, Kaasa S, Fougner B, Zahlsen K, Aamo T, Fayers P, Borchgrevink PC. Influence on serum concentration of morphine, morphine-3-glucuronide and morphine-6-glucuronide: A prospective survey in 300 patients. Acta Anaesth Scand, 2003; 47: 725-31
Klepstad P, Borchgrevink PC, Dale O, Zahlsen K, Aamo T, Fayers P, Fougner B Kaasa S. Relation between serum concentration of morphine, morphine-3-glucuronide and morphine-6-glucuronide and clinical observations: A prospective survey in 300 patients. Palliative Medicine 2003; 679-687
Dale O, Bergum H, Lund T, Nilsen T, Aadahl P, Stenseth R. A validated method for rapid analysis of ethane in breath and its application in kinetic studies in human volunteers. Free Radical Research 2003; 37: 815-21
Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single dose tranexamic acid reduces postoperative bleeding following coronary surgery in patients treated with aspirin until surgery. Anesth Analg 2003; 96:923-8
Kvalsvik O, Borchgrevink PC, Hagen L, Dale O. Rectal paracetamol combined with patient controlled morphine injection after hysterectomy. A double blind, randomised, placebo controlled evaluation of analgesia and morphine consumption. Acta Anaesth Scand 2003; 47:451-456
II. Reviews and editorials, book chapters
Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008; 2(7):879-89.
Klepstad P, Guttormsen AB, Dale O. Common sense won: engagement from experts repealed Norwegian restrictions for ICU research Intensive Care Med 2007;33:1827-8
Dale O, Lund T, Bergum H, Nilsen T, Aadahl P, Stenseth R. Serial samples of breath ethane can also be analyzed by gas-chromatography.Respir Med Respir Med. 2007 :679.
Pedersen TF, Torbjørnsen ML, Klepstad P, Sunde K, Dale O.Terapeutisk hypotermi: Fysiologiske, kliniske og farmakologiske aspekter. Tidsskr Nor Laegeforen. 2007; 18;127:163-6.
Dale O. Opioid drugs via other routes. In Davis A (ed) Cancer –related breakthrough pain. Oxford University Press, New York, 2006, pp 73-82
Klepstad P, Dale O. Further restrictions for ICU research.
Intensive Care Med. 2006 J32:175.
Dale O, Klepstad P. The Norwegian biobank legislation blocks research in critical care patients. Tidsskr Nor Laegeforen. 2005;125:2524
Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005;49:902-8.
Dale O, Kaasa S. Biology and pharmacology of the older patient patient: Start low- go slow. Eur J Palliative Care 2005; 12 (2 Suppl): 27-30
Dale O, Klepstad P, Kaasa S. The European Union- not united in opioid use. Palliative Medicine 2005 ; 19; 1-2
Kjesbu SS, Moksnes K, Klepstad P, Knobel H, K Kaasa S, Dale O. Application of pupillometry and pupillary reactions in medical research. Tidsskr Nor Lægeforen 2005; 125:29-32
Kaasa S, Dale O. Building up research in palliative care - a historical perspective–and a case for the future. Clinics in Geriatric Medicine. Clin Geriatr Med 2005;21: 81-92
Dale, Ola. Dårlig forskning er uetisk: Vitenskaplig holdbarhet og forskningsetikk i praksis. I: Festskrift - seksjon lindrende behandling gjennom 10 år. Trondheim: NTNU og St. Olavs hospital 2004. ISBN 82-303-0311-8. s. 156-61 http://www.medisin.ntnu.no/ikm/kreft/slb/Dokument/festskrift.pdf
Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesth Scand 2003, 241-59.
